NASDAQ:XOMA

XOMA (XOMA) Stock Forecast, Price & News

$18.16

-1.66 (-8.38%)

(As of 06/6/2023 ET)

Compare

Today's Range: $18.05
▼
$19.95
50-Day Range: $17.00
▼
$22.23
52-Week Range: $15.68
▼
$32.08

Volume: 29,151 shs
Average Volume: 39,663 shs
Market Capitalization: $208.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $69.00

XOMA MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 280.0% Upside
$69.00 Price Target
Short Interest: Bearish
4.98% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.22
Upright™ Environmental Score
News Sentiment: 0.78
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$157,134 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.44) to ($0.45) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

373rd out of 982 stocks

Pharmaceutical Preparations Industry

178th out of 475 stocks

3.5

Analyst's Opinion

Consensus Rating
XOMA has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $69.00, XOMA has a forecasted upside of 280.0% from its current price of $18.16.
Amount of Analyst Coverage
XOMA has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
4.98% of the outstanding shares of XOMA have been sold short.
Short Interest Ratio / Days to Cover
XOMA has a short interest ratio ("days to cover") of 19.9, which indicates bearish sentiment.
Change versus previous month
Short interest in XOMA has recently increased by 1.86%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
XOMA does not currently pay a dividend.
Dividend Growth
XOMA does not have a long track record of dividend growth.

3.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
XOMA has received a 26.63% net impact score from Upright. The largest positive contribution comes from its "Distributing knowledge" impact, which is false driven by its "Mutual funds investing in the pharmaceuticals industry" product. See details.
Environmental Sustainability
The Environmental Impact score for XOMA is -0.22.

3.2

News and Social Media Coverage

News Sentiment
XOMA has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for XOMA this week, compared to 1 article on an average week.
Search Interest
2 people have searched for XOMA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, XOMA insiders have bought more of their company's stock than they have sold. Specifically, they have bought $157,134.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 5.20% of the stock of XOMA is held by insiders.
Percentage Held by Institutions
54.89% of the stock of XOMA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for XOMA are expected to grow in the coming year, from ($1.44) to ($0.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of XOMA is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of XOMA is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
XOMA has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About XOMA (NASDAQ:XOMA) Stock

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

Receive XOMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

XOMA Stock News Headlines

June 4, 2023 | americanbankingnews.com

Bradley Sitko Acquires 1,500 Shares of XOMA Co. (NASDAQ:XOMA) Stock

May 28, 2023 | americanbankingnews.com

Insider Buying: XOMA Co. (NASDAQ:XOMA) CIO Purchases $16,150.00 in Stock

June 7, 2023 | Edge On The Street (Ad)

The $193 Billion US-China War You Don't Know About

They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.

May 28, 2023 | americanbankingnews.com

XOMA Co. (NASDAQ:XOMA) CEO Owen Hughes Purchases 968 Shares

May 24, 2023 | msn.com

XOMA's Return On Capital Employed Insights

May 24, 2023 | americanbankingnews.com

Bradley Sitko Acquires 1,000 Shares of XOMA Co. (NASDAQ:XOMA) Stock

May 23, 2023 | seekingalpha.com

XOMAP XOMA Corporation 8.625% CUM PERP PFD SER A

May 19, 2023 | americanbankingnews.com

XOMA (NASDAQ:XOMA) Receives New Coverage from Analysts at StockNews.com

June 7, 2023 | Edge On The Street (Ad)

The $193 Billion US-China War You Don't Know About

May 17, 2023 | americanbankingnews.com

XOMA Co. (NASDAQ:XOMA) CIO Bradley Sitko Buys 2,000 Shares of Stock

May 16, 2023 | finance.yahoo.com

Shareholders in XOMA (NASDAQ:XOMA) are in the red if they invested five years ago

May 11, 2023 | finance.yahoo.com

Acorda Therapeutics Reports First Quarter 2023 Financial Results

May 10, 2023 | msn.com

XOMA: Q1 Earnings Insights

May 10, 2023 | msn.com

XOMA GAAP EPS of -$0.98, revenue of $0.44M

May 9, 2023 | finance.yahoo.com

XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy

April 26, 2023 | finance.yahoo.com

XOMA to Present at H.C. Wainwright BioConnect Investor Conference

March 30, 2023 | finance.yahoo.com

XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio

March 10, 2023 | finance.yahoo.com

XOMA Full Year 2022 Earnings: Revenues Beat Expectations, EPS In Line

March 9, 2023 | finance.yahoo.com

XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy

March 6, 2023 | finance.yahoo.com

XOMA Corporation's (NASDAQ:XOMA) largest shareholders are individual investors with 37% ownership, hedge funds own 32%

March 6, 2023 | marketwatch.com

2023-2029 Acute Coronary Syndrome Therapeutics Market Size and Growth Analysis | Research Report by Absolute Reports

February 28, 2023 | prnewswire.com

HONOR Magic5 Pro занял верхнюю строчку рейтинга DXOMARK благодаря камере и дисплею

February 28, 2023 | prnewswire.com

HONOR Magic5 Pro je na čele rebríčka fotoaparátov a displejov DXOMARK

February 28, 2023 | finance.yahoo.com

XOMA to Present at 43rd Annual Cowen Health Care Conference

February 22, 2023 | prnewswire.com

Le HONOR Magic5 Lite est lancé sur les marchés européens et décroche la première place du classement mondial des batteries de DXOMARK

February 14, 2023 | finance.yahoo.com

XOMA Corporation (XOMA) Stock Historical Prices & Data - Yahoo Finance

February 8, 2023 | marketwatch.com

Botulism Illness Market to Grow Significantly by Leading Players 2023 to 2028

See More Headlines

XOMA Price History

30 days | 90 days | 365 days | Advanced Chart

XOMA Company Calendar

Last Earnings: 3/09/2023
Today: 6/06/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:XOMA
CUSIP: 98419J10
CIK: 791908
Web: www.xoma.com
Phone: (510) 204-7200
Fax: 510-649-7571
Employees: 12
Year Founded: 1981

Price Target and Rating

Average Stock Price Forecast: $69.00
High Stock Price Forecast: $69.00
Low Stock Price Forecast: $69.00
Forecasted Upside/Downside: +280.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.63)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,100,000.00
Net Margins: -774.65%
Pretax Margin: -734.35%
Return on Equity: -20.65%
Return on Assets: -18.11%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.47
Quick Ratio: 4.47

Sales & Book Value

Annual Sales: $3.36 million
Price / Sales: 62.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.83 per share
Price / Book: 1.68

Miscellaneous

Outstanding Shares: 11,461,000
Free Float: 10,865,000
Market Cap: $208.13 million
Optionable: Not Optionable
Beta: 0.85

Social Links

Key Executives

Owen Patrick Hughes
Chairman & Chief Executive Officer

Thomas Burns
Chief Financial Officer & Senior VP-Finance

Bradley J. Sitko
Chief Investment Officer

Juliane Snowden
Investor Relations Contact

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XOMA Stock - Frequently Asked Questions

Should I buy or sell XOMA stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XOMA shares.
View XOMA analyst ratings or view top-rated stocks.
What is XOMA's stock price forecast for 2023?: 1 Wall Street research analysts have issued 1 year price objectives for XOMA's shares. Their XOMA share price forecasts range from $69.00 to $69.00. On average, they predict the company's share price to reach $69.00 in the next year. This suggests a possible upside of 280.0% from the stock's current price.
View analysts price targets for XOMA or view top-rated stocks among Wall Street analysts.
How have XOMA shares performed in 2023?: XOMA's stock was trading at $18.40 at the start of the year. Since then, XOMA stock has decreased by 1.3% and is now trading at $18.16.
View the best growth stocks for 2023 here.
When is XOMA's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our XOMA earnings forecast.
How were XOMA's earnings last quarter?: XOMA Co. (NASDAQ:XOMA) announced its earnings results on Thursday, March, 9th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $1.49 million for the quarter, compared to the consensus estimate of $1.62 million. XOMA had a negative trailing twelve-month return on equity of 20.65% and a negative net margin of 774.65%.
What is John Varian's approval rating as XOMA's CEO?: 11 employees have rated XOMA Chief Executive Officer John Varian on Glassdoor.com. John Varian has an approval rating of 73% among the company's employees.

What other stocks do shareholders of XOMA own?: Based on aggregate information from My MarketBeat watchlists, some companies that other XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), OPKO Health (OPK), Uranium Energy (UEC), Gilead Sciences (GILD), NXP Semiconductors (NXPI) and Ekso Bionics (EKSO).
What is XOMA's stock symbol?: XOMA trades on the NASDAQ under the ticker symbol "XOMA."
Who are XOMA's major shareholders?: XOMA's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (31.71%), FMR LLC (10.77%), Stonepine Capital Management LLC (2.78%), Acuitas Investments LLC (0.76%), Geode Capital Management LLC (0.71%) and Susquehanna International Group LLP (0.44%). Insiders that own company stock include Bradley Sitko, Bvf Partners L P/Il, James R Neal, James R Neal, Matthew D Perry, Owen Hughes, Thomas M Burns and Value Fund L P Biotechnology.
View institutional ownership trends.
How do I buy shares of XOMA?: Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is XOMA's stock price today?: One share of XOMA stock can currently be purchased for approximately $18.16.
How much money does XOMA make?: XOMA (NASDAQ:XOMA) has a market capitalization of $208.13 million and generates $3.36 million in revenue each year. The biotechnology company earns $-17,100,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis.
How can I contact XOMA?: XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The official website for the company is www.xoma.com. The biotechnology company can be reached via phone at (510) 204-7200, via email at jsnowden@oratoriumgroup.com, or via fax at 510-649-7571.

This page (NASDAQ:XOMA) was last updated on 6/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial